Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Common Stock Issued
Cash raised by issuing new shares.
Harrow Health, Inc.NASDAQ: HROW
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued grows, but more slowly than its trailing trend
Q1 FY2026 common stock issued of $25K rose 8.7% year over year, behind the +87.2% change in trailing-twelve-month common stock issued. Sequentially, it fell 86.1% from the prior quarter. Over 3 fiscal years it compounded at -72.6% a year.
Context
- Common stock issued amounted to 0.2% of revenue in FY2025, up 0.2 pp from a year earlier.
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +8.7% toward the trailing-twelve-month pace of +87.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 467K USD
- Year-over-year change
- —
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 467K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 64.52M | +184.8% |
| FY2022 | 2022-12-31 | 22.66M | — |
| FY2021 | 2021-12-31 | 0 | — |
Common Stock Issued vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +87.2% is the 4th highest of 7, against a peer median of +257.1%.
- Common stock issued amounts to 0.1% of revenue for HROW, versus a peer median of 1689.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $557.83M USD | +54804.7% | +742.3% | 1072.0% | |
| LTM Sep 2026 | $187.21M USD | +12713.7% | +351.0% | — | |
| LTM Mar 2026 | $175.68M USD | +6.6% | +662.5% | 2307.0% | |
| LTM Sep 2026 | $115.45M USD | -19.8% | +24.2% | 16.9% | |
| LTM Mar 2026 | CHF 107.17M CHF | -25.5% | — | 21263.3% | |
| LTM Mar 2026 | $44.67M USD | +507.6% | -8.3% | 13408.7% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $5.92M USD | — | — | — |
| LTM Jun 2026 | $2M USD | — | — | 0.0% | |
| LTM Mar 2026 | $367K USD | +87.2% | -72.6% | 0.1% | |
| Peer median (excluding HROW) | — | +257.1% | +351.0% | 1689.5% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Depreciation & Amortization | 2.4M | 3.67M | 12.34M | 14.54M | 19.68M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.75M | 7.97M | 15.7M | 17.62M | 12.5M |
| Change in Working Capital | (253K) | (5.57M) | (7.14M) | (44.63M) | 185K |
| Accounts Receivables | (1.83M) | (1.86M) | (30.34M) | (80.23M) | 5.01M |
| Inventory | (255K) | (2.32M) | (4.33M) | 165K | (2.82M) |
| Accounts Payables | 1.73M | 933K | 31.8M | 37.5M | (4.61M) |
| Other Working Capital | 103K | (2.32M) | (4.26M) | (2.06M) | 2.6M |
| Other Non-Cash Items | 15.2M | 9.72M | 7.35M | 7.75M | 16.64M |
| Operating Cash Flow | 5.08M | 1.71M | 3.84M | (22.2M) | 43.86M |
| Capital Expenditures | (28.51M) | (7.77M) | (152.55M) | (38.67M) | (1.1M) |
| Acquisitions (Net) | 9.83M | 0 | 0 | 0 | (4.36M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 9.83M | 0 | 0 | 5.51M | 0 |
| Other Investing Activities | (36.55M) | 854K | (151.09M) | (37.08M) | (215K) |
| Investing Cash Flow | (18.69M) | (1.74M) | (152.55M) | (33.16M) | (5.46M) |
| Debt Repayment | 71.07M | 31.72M | 74.64M | 29.78M | 11.84M |
| Common Stock Issued | 0 | 22.66M | 64.52M | 0 | 467K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (127K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | (234K) | (12.63M) | (1.25M) | (25.04M) |
| Financing Cash Flow | 51.47M | 54.14M | 126.53M | 28.53M | (12.72M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.87M | 54.1M | (22.19M) | (26.84M) | 25.68M |
| Free Cash Flow | (23.43M) | (6.07M) | (148.71M) | (60.88M) | 42.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.